Literature DB >> 26438440

OSNA-Assisted Molecular Staging in Colorectal Cancer: A Prospective Multicenter Trial in Japan.

Hirofumi Yamamoto1,2, Naohiro Tomita3, Masafumi Inomata4, Tomohisa Furuhata5, Yasuhiro Miyake6, Shingo Noura7, Takeshi Kato8, Kohei Murata9, Shigeoki Hayashi10, Seiji Igarashi11, Michio Itabashi12, Shingo Kameoka12, Nariaki Matsuura13.   

Abstract

BACKGROUND: We previously reported that the one-step nucleic acid amplification (OSNA) assay provided a judgment performance for colorectal cancer equivalent to a 2-mm-interval histopathological examination of lymph nodes (concordance 97.1 %, n = 385 lymph nodes). In this prospective multicenter study, we uncovered an OSNA-assisted pathology to detect lymph node metastasis.
METHODS: A total of 204 (50 stage I, 74 stage II, and 80 stage III) colorectal cancer patients. All 4324 lymph nodes were examined by the standard histology (one-slice H&E staining) and 1925 lymph nodes (44.5 %) of them were also subject to the OSNA analysis.
RESULTS: The concordance rate between 1 slice hematoxylin/eosin and OSNA assay was 95.7 % (1,842/1925 lymph nodes). The sensitivity and specificity of the OSNA assay were 86.2 % (125/145) and 96.5 % (1717/1780), respectively. Among 124 node-negative patients (pN0), the respective upstaging rates of pStages I, IIA, IIB, and IIC were 2.0 % (1/50), 17.7 % (11/62), 12.5 % (1/8), and 25 % (1/4). OSNA-positive patients had deeper invasion to the colonic wall and severe lymphatic invasion (P = 0.048 and P = 0.004, respectively). The sum of the quantitative results of OSNA and total tumor load increased as the number of metastasized lymph nodes increased: 1550 copies/μL in pN0, 24,050 copies/μL in pN1, and 90,600 copies/μL in pN2.
CONCLUSIONS: The present study on colorectal cancer provided fundamental data regarding OSNA-assisted pathology of lymph node metastasis in Japan.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26438440     DOI: 10.1245/s10434-015-4880-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

Review 1.  Is it time for one-step nucleic acid amplification (OSNA) in colorectal cancer? A systematic review and meta-analysis.

Authors:  J B Wild; N Iqbal; J Francombe; T Papettas; D S Sanders; S Ramcharan
Journal:  Tech Coloproctol       Date:  2017-09-08       Impact factor: 3.781

Review 2.  One-step nucleic acid amplification (OSNA): where do we go with it?

Authors:  Yasuhiro Tamaki
Journal:  Int J Clin Oncol       Date:  2016-08-22       Impact factor: 3.402

3.  Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma.

Authors:  Natalia Rakislova; Carla Montironi; Iban Aldecoa; Eva Fernandez; Josep Antoni Bombi; Mireya Jimeno; Francesc Balaguer; Maria Pellise; Antoni Castells; Miriam Cuatrecasas
Journal:  J Transl Med       Date:  2017-01-14       Impact factor: 5.531

4.  Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden.

Authors:  Iban Aldecoa; Carla Montironi; Nuria Planell; Maria Pellise; Gloria Fernandez-Esparrach; Angels Gines; Salvadora Delgado; Dulce Momblan; Leticia Moreira; Maria Lopez-Ceron; Natalia Rakislova; Graciela Martinez-Palli; Jaume Balust; Josep Antoni Bombi; Antonio de Lacy; Antoni Castells; Francesc Balaguer; Miriam Cuatrecasas
Journal:  Surg Endosc       Date:  2016-06-20       Impact factor: 4.584

5.  Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma.

Authors:  Sherley Diaz-Mercedes; Ivan Archilla; Jordi Camps; Antonio de Lacy; Iñigo Gorostiaga; Dulce Momblan; Ainitze Ibarzabal; Joan Maurel; Nuria Chic; Josep Antoni Bombí; Francesc Balaguer; Antoni Castells; Iban Aldecoa; Josep Maria Borras; Miriam Cuatrecasas
Journal:  Appl Health Econ Health Policy       Date:  2019-10       Impact factor: 2.561

6.  Molecular Lymph Node Staging with One-Step Nucleic Acid Amplification and its Prognostic Value for Patients with Colon Cancer: The First Follow-up Study.

Authors:  Benjamin Weixler; Sofia Teixeira da Cunha; René Warschkow; Nicolas Demartines; Ulrich Güller; Andreas Zettl; Alexander Vahrmeijer; Cornelis J H van de Velde; Carsten T Viehl; Markus Zuber
Journal:  World J Surg       Date:  2021-01-29       Impact factor: 3.352

7.  Molecularly determined total tumour load in lymph nodes of stage I-II colon cancer patients correlates with high-risk factors. A multicentre prospective study.

Authors:  Iban Aldecoa; Begoña Atares; Jordi Tarragona; Laia Bernet; Jose Domingo Sardon; Teresa Pereda; Carlos Villar; M Carmen Mendez; Elvira Gonzalez-Obeso; Kepa Elorriaga; Guadalupe Lopez Alonso; Javier Zamora; Nuria Planell; Jose Palacios; Antoni Castells; Xavier Matias-Guiu; Miriam Cuatrecasas
Journal:  Virchows Arch       Date:  2016-07-22       Impact factor: 4.064

8.  One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer.

Authors:  Francesco Fanfani; Giorgia Monterossi; Viola Ghizzoni; Esther D Rossi; Giorgia Dinoi; Frediano Inzani; Anna Fagotti; Salvatore Gueli Alletti; Francesca Scarpellini; Camilla Nero; Angela Santoro; Giovanni Scambia; Gian F Zannoni
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

9.  Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Authors:  P García-Alfonso; R García-Carbonero; J García-Foncillas; P Pérez-Segura; R Salazar; R Vera; S Ramón Y Cajal; J Hernández-Losa; S Landolfi; E Musulén; M Cuatrecasas; S Navarro
Journal:  Clin Transl Oncol       Date:  2020-05-16       Impact factor: 3.405

10.  Ultrastaging Using Ex Vivo Sentinel Lymph Node Mapping and One-Step Nucleic Acid Amplification (OSNA) in Gastric Cancer: Experiences of a European Center.

Authors:  Bruno Märkl; Bianca Grosser; Kerstin Bauer; Dmytro Vlasenko; Gerhard Schenkirsch; Andreas Probst; Bernadette Kriening
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.